Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > The smart ones did not sell their shares..

<< Previous

Bullboard Posts

Next >>

Comment by Oenophileon Oct 28, 2020 8:11pm

165 Views

Post# 31800529

RE:RE:RE:The smart ones did not sell their shares..

Might Kalytera have enough data to release their GvHD therapeutic in the EU with a post market trial? Phase 3 only required 25 patients. They pretty much approve anything in Europe - look at NeoVasc's device for refractory angina. EU approved 8 years ago, FDA advisory committee completely trashed their presentation/data yesterday. Might also try compassionate use in the US? Trying to be positive about this. Still think R107 for Covid is worthless.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”